Ignite Creation Date:
2025-12-25 @ 1:33 AM
Ignite Modification Date:
2025-12-25 @ 11:47 PM
Study NCT ID:
NCT04995094
Status:
WITHDRAWN
Last Update Posted:
2021-11-05
First Post:
2021-07-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
Sponsor:
HiberCell, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-08-15
Start Date Type:
ACTUAL
Primary Completion Date:
2023-02-18
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-05-18
Completion Date Type:
ESTIMATED
First Submit Date:
2021-07-19
First Submit QC Date:
None
Study First Post Date:
2021-08-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-10-29
Last Update Post Date:
2021-11-05
Last Update Post Date Type:
ACTUAL